Cefprozil News
FDA approves Ranbaxy's drug to treat infections
The Food and Drug Administration has given Ranbaxy Pharmaceuticals Inc. approval to manufacture and market a generic drug for treating infections associated with bronchitis and tonsillitis.
A pooled analysis of seven randomized crossover studiesof the palatability of cefdinir oral suspension versus amoxicillin/clavulanate potassium, cefprozil, azithromycin, and amoxicillin in children aged 4 to 8 years
This analysis of the results of 7 trialscompared the taste and smell acceptability scores of cefdinir oral suspension and 4 other pediatric antibiotic oral suspensions—amoxicillin/clavulanate potassium, cefprozil, azithromycin,...
US FDA approves Lupin's cefprozil suspension, Orchid's tablets
Lupin Ltd has announced having received the US FDA approval for its abbreviated new drug application (ANDA) for cefprozil oral suspension in dosages of 125mg per 5ml and 250mg per 5ml.
Staphylococcal skin infections in children: rational drug therapy recommendations
Staphylococcus aureus remains one of the most common and troublesome of bacteria causing disease in humans, despite the development of effective antibacterials and improvement in hygiene.
Cefprozil in the treatment of chronic maxillary sinusitis. Clinical and microbiological effectiveness and penetration into sinuses examination
40 patients with exacerbation of a chronic maxillary sinusitis were examined. Sinus puncture was performed (sinoject) in all of the patients.
Displaying results 6 to 10 out of 10